Search clinical trials for: AK105

Total 151 results

Akeso

Recruiting

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
Henan Cancer Hospital

Recruiting

Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Tianjin Medical University Cancer Institute and...

Enrolling by invitation

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

Recurrent/Refractory Classical Hodgkin's Lymphoma

China
Akeso

Completed

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

Hodgkin's Lymphoma

China
West China Hospital

Not yet recruiting

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Breast Cancer

China
Akeso

Completed

A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

HCC | Lung Cancer | Solid Tumor

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Akeso
Akeso Tiancheng, Inc

Active, not recruiting

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Cervical Cancer
Sun Yat-sen University

Not yet recruiting

Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Akeso

Not yet recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib | Anti-PD-1 Antibody | Advanced Pancreatic Cancer

China
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Advanced Head, Neck and Chest Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

MSI-H or dMMR Advanced Solid Tumors

China
M.D. Anderson Cancer Center

Recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
Akesobio Australia Pty Ltd

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Advanced or Metastatic Solid Tumours

Australia
Akeso

Not yet recruiting

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Vulvar Cancer

China
Akeso

Not yet recruiting

AK104 in Neoadjuvant Treatment of Cervical Cancer

Cervical Cancer

China
Akeso
Akeso Tiancheng, Inc

Completed

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Akeso

Not yet recruiting

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Healthy Male Subjects
West China Second University Hospital
The Affiliated Hospital Of Southwest Medical University; Afﬁliated Hospital...

Recruiting

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Cervical Cancer

China
Chinese PLA General Hospital

Not yet recruiting

A Study of Combination Therapy in NSCLC

Non-small Cell Lung Cancer
Akeso

Completed

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Psoriasis Vulgaris

China
Akeso
AD Pharmaceuticals Co., Ltd.

Completed

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Hypercholesterolaemia

China
Acorda Therapeutics
United States Department of Defense; DP Clinical, Inc.

Terminated

AC105 in Patients With Acute Traumatic Spinal Cord Injury (AC105)

Acute Spinal Cord Injury
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaborators

Recruiting

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Immunotherapy | Second-line Treatment

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Akeso

Not yet recruiting

A Phase I Clinical Trial of AK115 in Healthy Subjects

Healthy Volunteers
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
Rigshospitalet, Denmark

Completed

Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

Head and Neck Cancer

Denmark
Shengjing Hospital

Not yet recruiting

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Akeso

Recruiting

Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

Plaque Psoriasis

China
Henan Cancer Hospital
Rongchang Biopharmaceutical; Zhengda Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

HER2-positive Gastric Cancer | Advanced Gastric Carcinoma

China
Akeso

Completed

A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

Solid Tumor

China
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Completed

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Melanoma | Advanced Solid Tumors

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

China
Asahi Kasei Pharma Corporation

Completed

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Poland, Ukraine, Germany, Hungary, United Kingdom, Slovakia, Czech Republic
Chongqing University Cancer Hospital
Akeso Pharmaceuticals, Inc.

Recruiting

Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

China
Harbin Medical University

Not yet recruiting

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China

3

Subscribe